Aarti Pharmalabs Ltd

Aarti Pharmalabs Ltd

$AARTIPHARMPharmaceuticalsNSEBSE

Aarti Pharmalabs Ltd (AARTIPHARM) last traded at ₹834, a market capitalisation of ₹7,560 crore, on a P/E of 35.1. Over the past 52 weeks the stock has ranged between ₹584 and ₹946. Aarti Pharmalabs Ltd last reported results for the quarter ended Jun 2026, with sales of ₹536 crore and net profit of ₹76 crore. The next scheduled event is a record date on 15 Sept 2026. Figures are as of 25 Aug 2026 and are not real time.

Aarti Pharmalabs Ltd share price and key metrics

Current price
₹834
Market cap
₹7,560 cr
Stock P/E
35.1
Book value
₹234
ROE
8.59%
ROCE
10.7%
Dividend yield
0.42%
52w high / low
946/584

Metrics as of 25 Aug 2026. Not real time.

Aarti Pharmalabs Ltd quarterly results

In the quarter ended Jun 2026, sales were ₹536 cr, up 38.9% from ₹386 cr a year earlier. Net profit was ₹76 cr, up 52.0% year on year.

Aarti Pharmalabs Ltd consolidated quarterly results, figures in ₹ crore
₹ croreSep 2024Dec 2024Mar 2025Jun 2025Sep 2025Dec 2025Mar 2026Jun 2026
Sales458538564386418432583536
Expenses364409418293344330470400
Operating profit941291469374102113136
OPM %20%24%26%24%18%24%19%25%
Other income45-2202148
Interest6107711131713
Depreciation2123232325292830
Profit before tax7210111565396382101
Tax %24%26%23%24%28%24%25%25%
Net profit5574885028486176
EPS (₹)6.038.169.755.463.085.296.748.40

Consolidated figures as reported by the company. Percentages are as published; totals may not sum exactly.

Aarti Pharmalabs Ltd annual results

Aarti Pharmalabs Ltd annual profit and loss, figures in ₹ crore
₹ croreMar 2021Mar 2022Mar 2023Mar 2024Mar 2025Mar 2026TTM
Sales01,2001,9451,8532,1151,8191,969
Operating profit0207342386464369426
OPM %17%18%21%22%20%22%
Net profit0122193217272175213
EPS (₹)21.3523.9330.0519.2723.51

TTM is the trailing twelve months to the most recent quarter.

Aarti Pharmalabs Ltd growth and returns

Compounded Sales Growth
10 Years
%
5 Years
%
3 Years
-2%
TTM
1%
Compounded Profit Growth
10 Years
%
5 Years
%
3 Years
-3%
TTM
-19%
Stock Price CAGR
10 Years
%
5 Years
%
3 Years
29%
1 Year
2%
Return on Equity
10 Years
%
5 Years
13%
3 Years
12%
Last Year
9%

Aarti Pharmalabs Ltd shareholding pattern

Promoters held 42.86% at Jun 2026, down from 43.72% at Jun 2025. FIIs 8.17% and DIIs 7.22%.

Aarti Pharmalabs Ltd shareholding pattern by quarter, in percent
% heldSep 2024Dec 2024Mar 2025Jun 2025Sep 2025Dec 2025Mar 2026Jun 2026
Promoters46.10%44.65%44.29%43.72%42.88%43.10%43.08%42.86%
FIIs7.38%8.64%7.36%7.34%8.02%7.69%8.39%8.17%
DIIs11.35%10.36%7.53%7.80%6.95%7.66%7.40%7.22%
Government0.01%0.01%0.01%0.01%0.01%0.01%0.01%0.01%
Public35.17%36.33%40.81%41.12%42.12%41.54%41.10%41.74%
No. of shareholders1,85,4361,85,1111,96,3141,87,0391,90,6551,84,4891,79,3731,76,506

As disclosed by the company to the exchanges. The last row is a count of shareholders, not a percentage.

Upcoming Aarti Pharmalabs Ltd events

The next scheduled event is a record date on 15 Sept 2026.

  • Record dateRecord date for final dividend payment of INR 2.00 per share

See the full results calendar for every Indian company reporting in the next 30 days.

Aarti Pharmalabs Ltd corporate filings

  • Announcement under Regulation 30 (LODR)-Newspaper PublicationCompany Updatelow impact
    Filing PDF

    Cruxal's analysis: Aarti Pharmalabs Ltd has submitted a routine disclosure under Regulation 30 of the SEBI…

    Read the full analysis
  • Disclosure as enclosedCorp. Actionlow impact
    Filing PDF

    Cruxal's analysis: Aarti Pharmalabs Limited has officially announced Tuesday, September 15, 2026, as the…

    Read the full analysis
  • Q1 FY 27 Earnings Call TranscriptCompany Updatehigh impact
    Filing PDF

    Cruxal's analysis: Aarti Pharmalabs reported strong Q1 FY27 standalone revenue of INR 535 crore, a 42% YoY…

    Read the full analysis
  • Audio Recording of Conference Call for Investor and AnalystsCompany Updatelow impact
    Filing PDF

    Cruxal's analysis: Aarti Pharmalabs Ltd has filed the audio recording of its conference call held with…

    Read the full analysis
  • Q1 FY 2027 Investor PresentationCompany Updatehigh impact
    Filing PDF

    Cruxal's analysis: Aarti Pharmalabs Limited reported strong Q1 FY27 consolidated financial performance with…

    Read the full analysis
  • Newspaper Publication on Financial ResultsCompany Updatelow impact
    Filing PDF

    Cruxal's analysis: Aarti Pharmalabs Limited has fulfilled its regulatory obligation under SEBI Listing…

    Read the full analysis
  • As enclosedCompany Updatelow impact
    Filing PDF

    Cruxal's analysis: Aarti Pharmalabs Limited has informed the exchanges that Mr. Rajendra Vallabhaji Gogri, a…

    Read the full analysis
  • Disclosure as enclosedCompany Updatemedium impact
    Filing PDF

    Cruxal's analysis: Aarti Pharmalabs has formally approved a capacity addition project focused on its…

    Read the full analysis
  • Outcome of Board Meeting held on August 07, 2026.Board Meetinghigh impact
    Filing PDF

    Cruxal's analysis: Aarti Pharmalabs Limited reported a robust performance for the quarter ended June 30…

    Read the full analysis

This page shows filings on a one-hour delay. Sign in to see them as they land, with Cruxal's analysis of what each one means.

Track Aarti Pharmalabs Ltd

Cruxal reads every Aarti Pharmalabs Ltd filing as it lands, scores what it means for the stock, and emails you the ones that matter. Free to start.

Cruxal publishes market data and coverage for information only. Nothing here is investment advice.

Aarti Pharmalabs Ltd (AARTIPHARM) Results, Financials & Share Price | Cruxal